Search - tctmd.com

Displaying 501 - 520 of 997

Sort: Relevancy | Date

News Conference News SCCT 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Yael L. Maxwell

July 15, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Daily News

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

Yael L. Maxwell

July 04, 2019

News Daily News

Elevated Non-HDL Cholesterol Levels Persist From Youth to Middle Age

Marcus A. Banks

July 03, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Daily News

Exposure to Air Pollution in China Tied to Increase in Coronary Calcium

Todd Neale

June 28, 2019

News Daily News

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

L.A. McKeown

June 25, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Yael L. Maxwell

May 02, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Lengthy Antibiotic Use Later in Life Tied to Higher CV Risk for Women

Caitlin E. Cox

April 25, 2019

Advertisement

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

Elevated Non-HDL Cholesterol Levels Persist From Youth to Middle Age

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Exposure to Air Pollution in China Tied to Increase in Coronary Calcium

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Lengthy Antibiotic Use Later in Life Tied to Higher CV Risk for Women

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content